argenx works in collaboration with Zai Lab with the purpose to accelerate new potential indications of clinical developments at a year by year basis. The duo commit to improving the lives of patients that suffer from cancer and severe autoimmune diseases. The license agreement of this takes place in Greater China, including mainland China, Taiwan, Hong Kong, and Macau.
argenx is building a progressive immunology company and the Zai Lab joins to expand their global footprint. In a statement by CEO of argenx, Tim Van Hauwermeiren, he states that "we aim to provide broad access to efgartigimod in these important markets as well as accelerate the number of autoimmune indications in clinical development [...] we believe that Zai Lab is the ideal partner for us ahead of our first potential approval of efgartigimod in generalized myasthenia gravis (gMG) in the U.S. and we are aligned in our mutual passion to bring potential innovative immunology therapies to patients in need.”
Image Credit: argenx